The Filings Report

10x Genomics, Inc. Class A Common Stock

TXGNasdaqCIK 1770787Healthcare / Diagnostics & Researchfiscal year ends December35 quarters since 2018

Revenue, Q3 FY2026
$151M
+1.1% on Q3 FY2025
Net income
−$19M
+29.3% on Q3 FY2025
Free cash flow
$15M
−65.1% on Q3 FY2025
Diluted EPS
$-0.15
+31.8% on Q3 FY2025
Revenue, TTM
$619M
trailing four quarters
Net margin, TTM
-10.8%
net income −$67M
Free cash flow, TTM
$94M
$100M less $6M capex
Cash and equivalents
—
long-term debt —, Sep 30, 2026
Shares, 12-month change
+4.2%
131M diluted weighted shares (no single count on the cover), Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$7.8B
at the close, buybacks

Latest quarter Q3 FY2026, filed November 6, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, 10x Genomics, Inc. Class A Common Stock reported revenue of $151M, +1.1% on Q3 FY2025, and net loss of $19M (+29.3%). Operating margin was −10.7%. Free cash flow, operating cash flow less capital expenditures, was $15M ($16M less $971K). Diluted earnings per share were $-0.15.

Share price

Daily candlesticks from November 11, 2024 to November 6, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

TXG daily priceSplit-adjusted, US dollars; an earnings release
Nov 6, 2026O $57.89 · H $61.99 · L $55.50 · C $59.28 · +2.10% on the dayOver the range: +356.00%, Nov 7, 2025 to Nov 6, 2026
$8.23$33$58$83$108Nov 25Jan 26Apr 26Jun 26Aug 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of November 6, 2026.

Revenue and net incomeRevenueNet income
−$100M$0$100M$200MQ4'22, Revenue: $156MQ4'22, Net income: −$17MQ4'22Q1'23, Revenue: $134MQ1'23, Net income: −$51MQ1'23Q2'23, Revenue: $147MQ2'23, Net income: −$62MQ2'23Q3'23, Revenue: $154MQ3'23, Net income: −$93MQ3'23Q4'23, Revenue: $184MQ4'23, Net income: −$49MQ4'23Q1'24, Revenue: $141MQ1'24, Net income: −$60MQ1'24Q2'24, Revenue: $153MQ2'24, Net income: −$38MQ2'24Q3'24, Revenue: $152MQ3'24, Net income: −$36MQ3'24Q4'24, Revenue: $165MQ4'24, Net income: −$49MQ4'24Q1'25, Revenue: $155MQ1'25, Net income: −$34MQ1'25Q2'25, Revenue: $173MQ2'25, Net income: $35MQ2'25Q3'25, Revenue: $149MQ3'25, Net income: −$27MQ3'25Q4'25, Revenue: $166MQ4'25, Net income: −$16MQ4'25Q1'26, Revenue: $151MQ1'26, Net income: −$13MQ1'26Q2'26, Revenue: $151MQ2'26, Net income: −$18MQ2'26Q3'26, Revenue: $151MQ3'26, Net income: −$19MQ3'26−$100M$0$100M$200MQ4'22, Revenue: $156MQ4'22, Net income: −$17MQ4'22Q1'23, Revenue: $134MQ1'23, Net income: −$51MQ1'23Q2'23, Revenue: $147MQ2'23, Net income: −$62MQ2'23Q3'23, Revenue: $154MQ3'23, Net income: −$93MQ3'23Q4'23, Revenue: $184MQ4'23, Net income: −$49MQ4'23Q1'24, Revenue: $141MQ1'24, Net income: −$60MQ1'24Q2'24, Revenue: $153MQ2'24, Net income: −$38MQ2'24Q3'24, Revenue: $152MQ3'24, Net income: −$36MQ3'24Q4'24, Revenue: $165MQ4'24, Net income: −$49MQ4'24Q1'25, Revenue: $155MQ1'25, Net income: −$34MQ1'25Q2'25, Revenue: $173MQ2'25, Net income: $35MQ2'25Q3'25, Revenue: $149MQ3'25, Net income: −$27MQ3'25Q4'25, Revenue: $166MQ4'25, Net income: −$16MQ4'25Q1'26, Revenue: $151MQ1'26, Net income: −$13MQ1'26Q2'26, Revenue: $151MQ2'26, Net income: −$18MQ2'26Q3'26, Revenue: $151MQ3'26, Net income: −$19MQ3'26−$100M$0$100M$200MQ4'22, Revenue: $156MQ4'22, Net income: −$17MQ1'23, Revenue: $134MQ1'23, Net income: −$51MQ1'23Q2'23, Revenue: $147MQ2'23, Net income: −$62MQ3'23, Revenue: $154MQ3'23, Net income: −$93MQ3'23Q4'23, Revenue: $184MQ4'23, Net income: −$49MQ1'24, Revenue: $141MQ1'24, Net income: −$60MQ1'24Q2'24, Revenue: $153MQ2'24, Net income: −$38MQ3'24, Revenue: $152MQ3'24, Net income: −$36MQ3'24Q4'24, Revenue: $165MQ4'24, Net income: −$49MQ1'25, Revenue: $155MQ1'25, Net income: −$34MQ1'25Q2'25, Revenue: $173MQ2'25, Net income: $35MQ3'25, Revenue: $149MQ3'25, Net income: −$27MQ3'25Q4'25, Revenue: $166MQ4'25, Net income: −$16MQ1'26, Revenue: $151MQ1'26, Net income: −$13MQ1'26Q2'26, Revenue: $151MQ2'26, Net income: −$18MQ3'26, Revenue: $151MQ3'26, Net income: −$19MQ3'26

Net income losses drawn in red.

Free cash flow
−$50M−$25M$0$25M$50MQ4'22, Free cash flow: −$26MQ4'22Q1'23, Free cash flow: −$9MQ1'23Q2'23, Free cash flow: −$37MQ2'23Q3'23, Free cash flow: −$41MQ3'23Q4'23, Free cash flow: $22MQ4'23Q1'24, Free cash flow: −$19MQ1'24Q2'24, Free cash flow: $5MQ2'24Q3'24, Free cash flow: $18MQ3'24Q4'24, Free cash flow: −$9MQ4'24Q1'25, Free cash flow: $32MQ1'25Q2'25, Free cash flow: $16MQ2'25Q3'25, Free cash flow: $43MQ3'25Q4'25, Free cash flow: $39MQ4'25Q1'26, Free cash flow: $25MQ1'26Q2'26, Free cash flow: $15MQ2'26Q3'26, Free cash flow: $15MQ3'26−$50M−$25M$0$25M$50MQ4'22, Free cash flow: −$26MQ4'22Q1'23, Free cash flow: −$9MQ1'23Q2'23, Free cash flow: −$37MQ2'23Q3'23, Free cash flow: −$41MQ3'23Q4'23, Free cash flow: $22MQ4'23Q1'24, Free cash flow: −$19MQ1'24Q2'24, Free cash flow: $5MQ2'24Q3'24, Free cash flow: $18MQ3'24Q4'24, Free cash flow: −$9MQ4'24Q1'25, Free cash flow: $32MQ1'25Q2'25, Free cash flow: $16MQ2'25Q3'25, Free cash flow: $43MQ3'25Q4'25, Free cash flow: $39MQ4'25Q1'26, Free cash flow: $25MQ1'26Q2'26, Free cash flow: $15MQ2'26Q3'26, Free cash flow: $15MQ3'26−$50M−$25M$0$25M$50MQ4'22, Free cash flow: −$26MQ1'23, Free cash flow: −$9MQ1'23Q2'23, Free cash flow: −$37MQ3'23, Free cash flow: −$41MQ3'23Q4'23, Free cash flow: $22MQ1'24, Free cash flow: −$19MQ1'24Q2'24, Free cash flow: $5MQ3'24, Free cash flow: $18MQ3'24Q4'24, Free cash flow: −$9MQ1'25, Free cash flow: $32MQ1'25Q2'25, Free cash flow: $16MQ3'25, Free cash flow: $43MQ3'25Q4'25, Free cash flow: $39MQ1'26, Free cash flow: $25MQ1'26Q2'26, Free cash flow: $15MQ3'26, Free cash flow: $15MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$100M$200M$300M$400MQ4'22, Cash and equivalents: $220MQ4'22Q1'23Q2'23Q3'23Q4'23, Cash and equivalents: $359MQ4'23Q1'24Q2'24Q3'24Q4'24, Cash and equivalents: $344MQ4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26$0$100M$200M$300M$400MQ4'22, Cash and equivalents: $220MQ4'22Q1'23Q2'23Q3'23Q4'23, Cash and equivalents: $359MQ4'23Q1'24Q2'24Q3'24Q4'24, Cash and equivalents: $344MQ4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26$0$100M$200M$300M$400MQ4'22, Cash and equivalents: $220MQ1'23Q3'23Q4'23, Cash and equivalents: $359MQ1'24Q3'24Q4'24, Cash and equivalents: $344MQ1'25Q3'25Q1'26Q3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed November 6, 2026.

10x Genomics, Inc. Class A Common Stock income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 6, 2026Q2 FY2026ended Jun 30, 2026filed Aug 7, 2026Q1 FY2026ended Mar 31, 2026filed May 8, 2026Q4 FY2025ended Dec 31, 2025filed Feb 13, 2026Q3 FY2025ended Sep 30, 2025filed Nov 7, 2025Q2 FY2025ended Jun 30, 2025filed Aug 8, 2025Q1 FY2025ended Mar 31, 2025filed May 9, 2025Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue151151151166149173155165+1.1%
Cost of revenue3839455349484954−22.5%
Gross profit113112106113100125105111+12.6%
Research and development—————————
Selling, general and administrative7679667775749094+0.9%
Operating income(16)(20)(17)(20)(32)30(39)(50)+50.2%
Other income (expense)(2)1444761−159.9%
Pretax income(18)(19)(13)(15)(28)37(34)(48)+34.5%
Income tax1(1)11(1)211+229.5%
Net income(19)(18)(13)(16)(27)35(34)(49)+29.3%
Diluted EPS ($)(0.15)(0.14)(0.10)—(0.22)0.28(0.28)—+31.8%
Diluted shares (millions)131130128—126125123——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed November 6, 2026.

10x Genomics, Inc. Class A Common Stock balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 6, 2026Q2 FY2026ended Jun 30, 2026filed Aug 7, 2026Q1 FY2026ended Mar 31, 2026filed May 8, 2026Q4 FY2025ended Dec 31, 2025filed Feb 13, 2026Q3 FY2025ended Sep 30, 2025filed Nov 7, 2025Q2 FY2025ended Jun 30, 2025filed Aug 8, 2025Q1 FY2025ended Mar 31, 2025filed May 9, 2025Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents———————344—
Short-term investments4950504950505049−0.2%
Total current assets719675670684660656580584+8.9%
Total assets1,0631,0301,0161,0411,027980903919+3.5%
Total current liabilities140119114153147112108118−4.7%
Long-term debt—————————
Total liabilities225205201245242207196209−7.1%
Stockholders’ equity838826814796785773707710+6.7%
Shares outstanding (millions)—————————

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed November 6, 2026.

10x Genomics, Inc. Class A Common Stock cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 6, 2026Q2 FY2026ended Jun 30, 2026filed Aug 7, 2026Q1 FY2026ended Mar 31, 2026filed May 8, 2026Q4 FY2025ended Dec 31, 2025filed Feb 13, 2026Q3 FY2025ended Sep 30, 2025filed Nov 7, 2025Q2 FY2025ended Jun 30, 2025filed Aug 8, 2025Q1 FY2025ended Mar 31, 2025filed May 9, 2025Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow16172641431834(7)−63.4%
Capital expenditures12221223+41.3%
Free cash flow (CFO − capex)15152539431632(9)−65.1%
Depreciation and amortization1010101010889−7.7%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 13, 2026.

Income statement

10x Genomics, Inc. Class A Common Stock income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 13, 2026FY2024ended Dec 31, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 16, 2023FY2021ended Dec 31, 2021filed Feb 18, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Feb 27, 2020FY2018ended Dec 31, 2018filed Nov 12, 2019FY2017ended Dec 31, 2017filed Nov 12, 2019
Revenue64361161951649029924614671
Cost of revenue1991962091207458612911
Gross profit44441440939641624018511861
Research and development—————————
Selling, general and administrative3163443432982582021318847
Operating income(61)(195)(265)(168)(52)(534)(31)(111)(18)
Other income (expense)2117176(1)00(2)0
Pretax income(40)(178)(249)(162)(54)(534)(31)(112)(19)
Income tax456458000
Net income(44)(183)(255)(166)(58)(543)(31)(112)(19)
Diluted EPS ($)(0.35)(1.52)(2.18)(1.46)(0.53)(5.37)(0.80)——
Diluted shares (millions)12512011711411010139——

Balance sheet

10x Genomics, Inc. Class A Common Stock balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 13, 2026FY2024ended Dec 31, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 16, 2023FY2021ended Dec 31, 2021filed Feb 18, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Feb 27, 2020FY2018ended Dec 31, 2018filed Nov 12, 2019FY2017ended Dec 31, 2017filed Nov 12, 2019
Cash and equivalents—3443592205876644246548
Short-term investments4949292100————
Total current assets684584596635748774481106—
Total assets1,0419199651,0291,01992946124—
Total current liabilities1531181271311101186332—
Long-term debt—————02025—
Total liabilities24520922422320119078101—
Stockholders’ equity796710741806818739420(220)(113)
Shares outstanding (millions)—————————

Cash flow statement

10x Genomics, Inc. Class A Common Stock cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 13, 2026FY2024ended Dec 31, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 16, 2023FY2021ended Dec 31, 2021filed Feb 18, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Feb 27, 2020FY2018ended Dec 31, 2018filed Nov 12, 2019FY2017ended Dec 31, 2017filed Nov 12, 2019
Operating cash flow1367(15)(34)(21)(218)35(76)(11)
Capital expenditures61249132101374364
Free cash flow (CFO − capex)130(6)(64)(165)(123)(255)(8)(83)(14)
Depreciation and amortization363636252114744
Share repurchases————————0
Dividends paid—————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 9, 2024 to November 9, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$12M
28 sales by 6 insiders; officers and directors $12M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$17M
50 sales by 6 insiders; officers and directors $17M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 22, 2026Suliman ShehnaazDirectoropen-market sale10b5-1292$78.20$23K29,223Sep 24, 2026
Sep 22, 2026Suliman ShehnaazDirectoropen-market sale10b5-1614$79.51$49K28,609Sep 24, 2026
Sep 22, 2026Suliman ShehnaazDirectoropen-market sale10b5-11,325$80.82$107K27,284Sep 24, 2026
Sep 22, 2026Suliman ShehnaazDirectoropen-market sale10b5-12,270$81.67$185K25,014Sep 24, 2026
Sep 22, 2026Suliman ShehnaazDirectoropen-market sale10b5-11,222$82.28$101K23,792Sep 24, 2026
Sep 22, 2026Saxonov SergeChief Executive Officer, Directoropen-market sale10b5-11,000$78.23$78K1MSep 24, 2026
Sep 22, 2026Saxonov SergeChief Executive Officer, Directoropen-market sale10b5-12,000$79.62$159K1MSep 24, 2026
Sep 22, 2026Saxonov SergeChief Executive Officer, Directoropen-market sale10b5-19,300$80.90$752K1MSep 24, 2026
Sep 22, 2026Saxonov SergeChief Executive Officer, Directoropen-market sale10b5-19,900$81.83$810K1MSep 24, 2026
Sep 22, 2026Saxonov SergeChief Executive Officer, Directoropen-market sale10b5-12,800$82.36$231K1MSep 24, 2026
Sep 9, 2026Taich AdamChief Financial Officeropen-market sale10b5-11,206$63.68$77K361,526Sep 11, 2026
Sep 9, 2026Taich AdamChief Financial Officeropen-market sale10b5-131,428$64.31$2M330,098Sep 11, 2026
Sep 9, 2026Taich AdamChief Financial Officeropen-market sale10b5-113,754$65.26$898K316,344Sep 11, 2026
Sep 3, 2026Stuelpnagel John RDirectoropen-market sale7,012$60.66$425K341,424Sep 8, 2026
Sep 3, 2026Stuelpnagel John RDirectoropen-market sale6,814$62.11$423K334,610Sep 8, 2026
Sep 3, 2026Stuelpnagel John RDirectoropen-market sale6,174$62.61$387K328,436Sep 8, 2026
Sep 1, 2026Saxonov SergeChief Executive Officer, Directorgift100$0.00—1MSep 3, 2026
Aug 26, 2026Saxonov SergeChief Executive Officer, Directoropen-market sale10b5-13,500$63.02$221K1MAug 28, 2026
Aug 26, 2026Saxonov SergeChief Executive Officer, Directoropen-market sale10b5-16,494$63.98$415K1MAug 28, 2026
Aug 26, 2026Saxonov SergeChief Executive Officer, Directoropen-market sale10b5-1492$64.75$32K1MAug 28, 2026
Aug 24, 2026Saxonov SergeChief Executive Officer, Directoropen-market sale18,545$63.02$1M1MAug 26, 2026
Aug 24, 2026Taich AdamChief Financial Officeropen-market sale17,166$63.02$1M362,732Aug 26, 2026
Aug 24, 2026Hindson Benjamin J.See Remarks, Directoropen-market sale13,818$63.02$871K488,182Aug 26, 2026
Aug 24, 2026Suliman ShehnaazDirectoropen-market sale10b5-1561$62.73$35K31,161Aug 26, 2026
Aug 24, 2026Suliman ShehnaazDirectoropen-market sale10b5-11,646$63.97$105K29,515Aug 26, 2026

Full insider history for 10x Genomics, Inc. Class A Common Stock, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held TXG in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded TXG by quarter.

FundManagerQuarterValueSharesWeightMove
Duquesne Family OfficeStanley DruckenmillerQ2 2026$15M403,1000.30%new

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
10x Genomics, Inc., CIK 1770787 on EDGAR
Extract generated
November 8, 2026
Withheld
none
Repaired
2 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2019, other income FY2020
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: CostOfRevenue
Gross profit: GrossProfit
Research and development: not filed
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): not filed

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 8, 2026.

JSON file
/data/financials/TXG.json